Experimental GBM treatment — DC Vax — is hoped to be moving forward in the UK
NW Biotherapeutics, maker of DC Vax to treat glioblastoma — applied for approval in the UK.
NW Biotherapeutics, maker of DC Vax to treat glioblastoma — applied for approval in the UK.
OurBrainBank is proud that the White House invited us to be part of the ambitious Cancer Moonshot effort. Read the latest from Washington DC.
Executive Director Kelli Duprey presented our poster about treatment disparities at SNO 2023
Clinical trial for people newly diagnosed with glioblastoma